PMID- 28546462
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20220408
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 22
IP  - 9
DP  - 2017 Sep
TI  - Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor 
      for All Patients in 2017!
PG  - 1125-1134
LID - 10.1634/theoncologist.2017-0009 [doi]
AB  - Hematopoietic stem cell transplant (HSCT) is potentially curative for a wide 
      variety of malignant diseases, including acute and leukemias, lymphoma, and 
      myelodysplasia. Choice of a stem cell donor is dependent on donor availability, 
      donor compatibility and health, recipient disease type, and recipient condition. 
      Current sources of stem cell donation for HSCT are matched sibling donors (MSDs), 
      matched unrelated donors (MUDs), 1-antigen mismatched unrelated donors (MMUDs), 
      haploidentical donors (haplo), and umbilical cord blood (UCB) units. 
      Historically, preferred donors for HSCT have been human leukocyte antigen 
      (HLA)-matched sibling donors; however, only about 30% of U.S. patients will have 
      a MSD available. The majority of patients referred for HSCT will require an 
      alternative donor graft: MUD, MMUD, UCB, or haplo. The likelihood of finding a 
      MUD varies depending on the ethnicity of the recipient. White Caucasians of 
      European descent have the greatest chance of finding a MUD. Chances of finding a 
      MUD are significantly less for African-American or Hispanic recipients due to HLA 
      polymorphisms. Therefore, MMUD, UCB, and haplo donor graft sources expand the 
      donor pool for recipients who do not have a MSD or MUD available. Given the 
      variety of different donor stem cell sources available today, nearly every 
      patient who needs an allogeneic HSCT has a potential donor in 2017. All 
      transplant-eligible patients with hematologic malignancies should be evaluated by 
      a transplant center to determine if HSCT is a viable treatment option for their 
      underlying disease process. IMPLICATIONS FOR PRACTICE: The goal of this review is 
      to increase the awareness of oncology practitioners to the availability of 
      alternative donor stem cell transplants for patients with hematologic 
      malignancies. Despite new agents, stem cell transplant remains the only curative 
      therapy for many patients with acute and chronic leukemia, myelodysplasia, and 
      lymphoma. Given the variety of different donor stem cell sources available today, 
      nearly every patient who needs an allogeneic stem cell transplant will have a 
      donor.
CI  - (c) AlphaMed Press 2017.
FAU - Kindwall-Keller, Tamila L
AU  - Kindwall-Keller TL
AD  - Department of Medicine, University of Virginia School of Medicine, and Stem Cell 
      Transplant Program, University of Virginia Cancer Center, Charlottesville, 
      Virginia, USA.
FAU - Ballen, Karen K
AU  - Ballen KK
AD  - Department of Medicine, University of Virginia School of Medicine, and Stem Cell 
      Transplant Program, University of Virginia Cancer Center, Charlottesville, 
      Virginia, USA KB3TC@virginia.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170525
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Allografts/immunology
MH  - Graft vs Host Disease/*immunology
MH  - HLA Antigens/immunology
MH  - Hematologic Neoplasms/*therapy
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods/trends
MH  - Hematopoietic Stem Cells/*immunology
MH  - Histocompatibility Testing/trends
MH  - Humans
MH  - Tissue Donors
MH  - Tissue and Organ Procurement/*methods/trends
MH  - Transplantation, Homologous/adverse effects/methods/trends
PMC - PMC5599191
OTO - NOTNLM
OT  - Cord blood
OT  - Haploidentical
OT  - Leukemia
OT  - Stem cell transplant
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2017/05/27 06:00
MHDA- 2018/05/22 06:00
PMCR- 2018/09/01
CRDT- 2017/05/27 06:00
PHST- 2017/01/10 00:00 [received]
PHST- 2017/04/13 00:00 [accepted]
PHST- 2017/05/27 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/05/27 06:00 [entrez]
PHST- 2018/09/01 00:00 [pmc-release]
AID - theoncologist.2017-0009 [pii]
AID - ONCO12165 [pii]
AID - 10.1634/theoncologist.2017-0009 [doi]
PST - ppublish
SO  - Oncologist. 2017 Sep;22(9):1125-1134. doi: 10.1634/theoncologist.2017-0009. Epub 
      2017 May 25.